• Xiangyi Zan, Yuping Wang, Junnian Shi, Lanting Zhao, Yan Zhao, Rong Liu, Yongning Zhou, Yixin Wan, and Cancer Biomarker Assessment Working Group.
• Department of Respiratory, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College.
• Medicine (Baltimore). 2019 Jun 1; 98 (24): e16028.

BackgroundMalignant pleural mesothelioma (MPM) is a highly invasive tumor caused primarily by asbestos exposure. In recent decades, the incidence of MPM has shown an increasing trend, posing a great threat to human health. Although there is currently no effective way to treat MPM, patients can survive for more than 5 years if the tumor is removed early. Several systematic reviews (SRs) have evaluated the diagnostic value of biomarkers for diagnosing MPM. However, no studies have been conducted to analyze the quality of these SRs and it remains unclear which biomarker is the excellent diagnostic test. This study aims to assess the methodological quality of the SRs and reanalyze the published data based on SRs to find the optimal biomarker for the early diagnosis of MPM.MethodsA systematic search will be performed in PubMed, Embase.com, the Cochrane Library of Systematic Reviews, and Web of Science to identify SRs reporting value of biomarkers for detecting MPM. We will evaluate the risk of bias of the included SRs according to the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) instrument. Standard pairwise meta-analysis and adjusted indirect comparison will be used to compare the diagnostic value of different biomarkers.ResultsThe results of this study will be submitted to a peer-reviewed journal for publication.ConclusionThis study will reanalyze the published data based on SRs to find a biomarker with the superior diagnostic performance for the diagnosis of MPM.Ethics And DisseminationEthics approval and patient consent are not required as this study is an overview based on published systematic reviews.Prospero Registration NumberCRD42019125880.

14 keywords...

hide…